Physician profile
Gary B Bell
NPI 1689640922
$1,376.22
in general payments reported to CMS, 2019-2025
21 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $365 · 2023: $582 · 2024: $272 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $250.57 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Emmaus Medical, INC. | $157.81 | 2025 | Endari |
| Abbvie INC. | $148.42 | 2022-2024 | Vraylar, Dalvance |
| Novo Nordisk INC | $135.23 | 2022-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $127.65 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $101.25 | 2022-2024 | Breztri, Airsupra |
| Abbott Laboratories | $83.61 | 2022-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.87 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $46.87 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $41.22 | 2022-2023 | |
| Dexcom, INC. | $34.23 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $25.92 | 2022-2023 | |
| Amgen INC. | $23.55 | 2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.46 | 2024 | Xifaxan, Trulance |
| Insulet Corporation | $21.59 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.27 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $18.19 | 2023 | Onpattro |
| Azurity Pharmaceuticals, INC. | $13.35 | 2023 | Horizant |
| Janssen Pharmaceuticals, INC | $13.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.74 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.